Literature DB >> 12709034

Comparing outcomes of different treatment regimens for severe haemophilia.

H M van den Berg1, K Fischer, J G van der Bom.   

Abstract

Published retrospective reports from France, the Netherlands and Sweden were analysed for data relating to the long-term outcomes (primarily the development of arthropathy) of three regimens for the management of severe haemophilia: on-demand treatment, intermediate-dose prophylaxis and high-dose prophylaxis. The mean annual consumption of factor concentrate was also compared. These data indicate that both prophylaxis regimens resulted in significantly improved long-term outcomes, as assessed by pain, clinical and radiological assessment scores. At the same time, the most recently reported annual factor consumption levels of these young adult patients are comparable in the on-demand and intermediate-dose prophylaxis cohorts, suggesting that the improvement in long-term clinical outcomes and reduced risk of arthropathy may lead to reduced factor consumption in adult patients who received early prophylactic therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12709034     DOI: 10.1046/j.1365-2516.9.s1.10.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  9 in total

Review 1.  Low Dose Prophylaxis in Hemophilia Care.

Authors:  Neeraj Sidharthan; Remya Sudevan
Journal:  Indian J Hematol Blood Transfus       Date:  2019-06-15       Impact factor: 0.900

2.  Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.

Authors:  Jerry S Powell; Neil C Josephson; Doris Quon; Margaret V Ragni; Gregory Cheng; Ella Li; Haiyan Jiang; Lian Li; Jennifer A Dumont; Jaya Goyal; Xin Zhang; Jurg Sommer; Justin McCue; Margaret Barbetti; Alvin Luk; Glenn F Pierce
Journal:  Blood       Date:  2012-01-05       Impact factor: 22.113

Review 3.  Primary prophylaxis in children with haemophilia.

Authors:  Antonio Coppola; Mirko Di Capua; Ciro De Simone
Journal:  Blood Transfus       Date:  2008-09       Impact factor: 3.443

4.  Persons with Haemophilia in Sweden- Experiences and Strategies in Everyday Life. A Single Centre Study.

Authors:  Elisabeth Brodin; Katharina S Sunnerhagen; Fariba Baghaei; Marie Törnbom
Journal:  PLoS One       Date:  2015-10-02       Impact factor: 3.240

Review 5.  Clinical utility and patient perspectives on the use of extended half-life rFIXFc in the management of hemophilia B.

Authors:  Maricel G Miguelino; Jerry S Powell
Journal:  Patient Prefer Adherence       Date:  2014-08-08       Impact factor: 2.711

6.  Musculoskeletal evaluation in severe haemophilia A patients from Latin America.

Authors:  M C Ozelo; P R Villaça; R Pérez-Bianco; M Candela; J Garcia-Chavez; B Moreno-Rodriguez; M B Rodrigues; I Rodriguez-Grecco; M H Solano; G Chumpitaz; M M Morales-Gana; A Ruiz-Sáez
Journal:  Haemophilia       Date:  2014-01       Impact factor: 4.287

Review 7.  Haemophilia and joint disease: pathophysiology, evaluation, and management.

Authors:  Karin Knobe; Erik Berntorp
Journal:  J Comorb       Date:  2011-12-27

8.  LongHest project: A prospective, observational study of extended half-life treatment in the musculoskeletal health of patients with severe haemophilia A.

Authors:  Rubén Cuesta-Barriuso; Raúl Pérez-Llanes; Elena Donoso-Úbeda; Roberto Ucero-Lozano
Journal:  Haemophilia       Date:  2022-05-13       Impact factor: 4.263

9.  Patient and parent preferences for characteristics of prophylactic treatment in hemophilia.

Authors:  Roberto Furlan; Sangeeta Krishnan; Jeffrey Vietri
Journal:  Patient Prefer Adherence       Date:  2015-11-23       Impact factor: 2.711

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.